Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-023150
Filing Date
2026-05-14
Accepted
2026-05-14 16:50:40
Documents
65
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 987984
2 EX-31.1 ex31-1.htm EX-31.1 18974
3 EX-31.2 ex31-2.htm EX-31.2 19127
4 EX-32.1 ex32-1.htm EX-32.1 7967
5 EX-32.2 ex32-2.htm EX-32.2 7969
6 GRAPHIC form10-q_002.jpg GRAPHIC 80359
  Complete submission text file 0001493152-26-023150.txt   6477689

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lixt-20260331.xsd EX-101.SCH 62796
8 XBRL CALCULATION FILE lixt-20260331_cal.xml EX-101.CAL 47502
9 XBRL DEFINITION FILE lixt-20260331_def.xml EX-101.DEF 229125
10 XBRL LABEL FILE lixt-20260331_lab.xml EX-101.LAB 471285
11 XBRL PRESENTATION FILE lixt-20260331_pre.xml EX-101.PRE 342893
68 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 922566
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39717 | Film No.: 26980009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)